Company: NCEL
Filing Date: 2025-10-10
Form Type: 6-K
Source: 0001213900-25-097887
Chunk: 1

Company: NewcelX Ltd.
Filing Date: 2025-10-10
Form: 6-K
Chunk 1
---
 and for the six months ended June 30, 2025, which are attached hereto as Exhibit 99.3.

<div align='center'>1

EXHIBIT INDEX</div>

| Exhibit 
 Number  
 99.1    
 99.2    |     | Description of Document                                                                                                                                            
 Unaudited Interim Condensed Financial Statements of Kadimastem Ltd. as of June 30, 2025 and December 31, 2024 and for the six months ended June 30, 2025 and 2024. 
 Audited Financial Statements of Kadimastem Ltd. as of and for the years ended December 31, 2024 and 2023.                                                          |
|:--------|:----|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 99.3    |     | Unaudited Pro Forma Condensed Combined Financial Statements of NLS Pharmaceutics Ltd. for the six months ended June 30, 2025.                                      |

<div align='center'>2

SIGNATURES</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.

| Date: October 9, 2025 | NLS Pharmaceutics Ltd. 
 By:                    | /s/ Alexander Zwyer |                         |
|:----------------------|:-----------------------|:--------------------|:------------------------|
|                       |                        | Name:               | Alexander Zwyer         |
|                       |                        | Title:              | Chief Executive Officer |

<div align='center'>3</div>